Full Text View
Tabular View
No Study Results Posted
Related Studies
The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment
This study has been completed.
Study NCT00103948   Information provided by Eisai Inc.

First Received on February 17, 2005.   Last Updated on March 31, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Impaired Cognition
Additional conditions recognized in this trial
CADASIL
Cognition Disorders
More general conditions related to this trial
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Cerebral Arterial Diseases
Cerebrovascular Disorders
Delirium, Dementia, Amnestic, Cognitive Disorders
Dementia
Dementia, Vascular
Genetic Diseases, Inborn
Intracranial Arterial Diseases
Mental Disorders
Nervous System Diseases
Vascular Diseases
Interventions listed in this trial
Aricept
Additional drug interventions recognized in this trial
Donepezil
More general drug interventions related to this trial
Central Nervous System Agents
Cholinergic Agents
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nootropic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Eisai Limited


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services